

Supplementary Figure S2: in vivo characterization of HC-5404. A) PK analysis of HC-5404 following single oral administration (PO). A dose-proportionate increase in exposure was observed across a 24 h period. B) Effect of HC-5404 on pPERK in 786-O tumors sampled 1, 4, 8, 12 h post last dose following 15 days of BID dosing. C) Final tumor volume from dose fractionation study analyzed by one-way ANOVA following homogeneity of variance tests. Data represent mean ± S.E.M., n=8 mice per group (*p<0.05; **p<0.01). D) Mouse pancreas sections following three weeks of treatment with HC-5404 at either 30 or 100 mg/kg PO, BID. The pancreas pictured on right was given a two-week washout period following treatment with 100 mg/kg PO BID, to demonstrate reversibility of the effect. E) pPERK/PERK protein ratio from 786-O xenografts treated with sunitinib (40 mg/kg; PO; QD) for one or two weeks. F) Quantification of pPERK/PERK levels following treatment with four VEGFR-TKIs and HC-5404. 786-O xenografts treated for 7 days.